Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma.

IF 1.8
Cornelius Busse, Marius Hörner, Babak Saravi, Lukas Haug, Sebastian Gubik, Alexander Kübler, Urs Müller-Richter, Andreas Rosenwald, Stefan Hartmann
{"title":"Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma.","authors":"Cornelius Busse, Marius Hörner, Babak Saravi, Lukas Haug, Sebastian Gubik, Alexander Kübler, Urs Müller-Richter, Andreas Rosenwald, Stefan Hartmann","doi":"10.1007/s10006-026-01638-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PD-L1 expression is an established predictive biomarker for immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC). However, the spatial heterogeneity of PD-L1 and additional biomarkers such as c-MET between primary tumors and lymph node metastases remains insufficiently characterized. Given the potential for compartment-specific biomarker differences between primary tumors and metastatic lesions, we investigated PD-L1 and c-MET expression patterns in matched primary tumors and lymph node metastases of OSCC patients.</p><p><strong>Methods: </strong>In this retrospective cohort study, PD-L1 expression (Tumor Proportion Score [TPS], Combined Positive Score [CPS]) and c-MET expression (H-score, percentage-based scoring) were analyzed by immunohistochemistry in primary tumors from 59 OSCC patients. Matched primary tumor-lymph node metastasis pairs were available for 24 patients and served as the basis for the paired spatial heterogeneity analyses. Biomarker concordance between primary tumors and metastases as well as associations with clinicopathologic parameters were evaluated.</p><p><strong>Results: </strong>Both PD-L1 and c-MET were frequently expressed in primary tumors but showed significantly lower expression levels in matched lymph node metastases. Higher PD-L1 expression in primary tumors was associated with nodal metastasis in exploratory analyses, whereas c-MET expression showed no significant association with nodal status. No significant correlation between PD-L1 and c-MET expression was observed. Furthermore, discordance of PD-L1 CPS status between primary tumors and lymph node metastases resulted in different biomarker classifications in a substantial subset of matched cases. In exploratory analyses, biomarker expression and primary tumor-lymph node discordance were not significantly associated with recurrence, although the limited number of events precludes definitive conclusions.</p><p><strong>Conclusions: </strong>Our findings demonstrate pronounced spatial heterogeneity of PD-L1 and c-MET expression in OSCC and reveal compartment-specific biomarker expression patterns between primary tumors and lymph node metastases. The observed discordance between tumor compartments warrants further investigation in larger prospective studies to determine its biological and potential clinical relevance for biomarker assessment in OSCC.</p>","PeriodicalId":520733,"journal":{"name":"Oral and maxillofacial surgery","volume":"30 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral and maxillofacial surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s10006-026-01638-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: PD-L1 expression is an established predictive biomarker for immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC). However, the spatial heterogeneity of PD-L1 and additional biomarkers such as c-MET between primary tumors and lymph node metastases remains insufficiently characterized. Given the potential for compartment-specific biomarker differences between primary tumors and metastatic lesions, we investigated PD-L1 and c-MET expression patterns in matched primary tumors and lymph node metastases of OSCC patients.

Methods: In this retrospective cohort study, PD-L1 expression (Tumor Proportion Score [TPS], Combined Positive Score [CPS]) and c-MET expression (H-score, percentage-based scoring) were analyzed by immunohistochemistry in primary tumors from 59 OSCC patients. Matched primary tumor-lymph node metastasis pairs were available for 24 patients and served as the basis for the paired spatial heterogeneity analyses. Biomarker concordance between primary tumors and metastases as well as associations with clinicopathologic parameters were evaluated.

Results: Both PD-L1 and c-MET were frequently expressed in primary tumors but showed significantly lower expression levels in matched lymph node metastases. Higher PD-L1 expression in primary tumors was associated with nodal metastasis in exploratory analyses, whereas c-MET expression showed no significant association with nodal status. No significant correlation between PD-L1 and c-MET expression was observed. Furthermore, discordance of PD-L1 CPS status between primary tumors and lymph node metastases resulted in different biomarker classifications in a substantial subset of matched cases. In exploratory analyses, biomarker expression and primary tumor-lymph node discordance were not significantly associated with recurrence, although the limited number of events precludes definitive conclusions.

Conclusions: Our findings demonstrate pronounced spatial heterogeneity of PD-L1 and c-MET expression in OSCC and reveal compartment-specific biomarker expression patterns between primary tumors and lymph node metastases. The observed discordance between tumor compartments warrants further investigation in larger prospective studies to determine its biological and potential clinical relevance for biomarker assessment in OSCC.

探讨口腔鳞癌中PD-L1和c-MET表达的空间异质性。
背景:PD-L1表达是复发或转移性头颈部鳞状细胞癌(HNSCC)(包括口腔鳞状细胞癌(OSCC))免疫检查点抑制剂治疗的预测性生物标志物。然而,PD-L1和其他生物标志物(如c-MET)在原发肿瘤和淋巴结转移之间的空间异质性仍未充分表征。考虑到原发肿瘤和转移灶之间可能存在的区室特异性生物标志物差异,我们研究了匹配的OSCC原发肿瘤和淋巴结转移患者中PD-L1和c-MET的表达模式。方法:在这项回顾性队列研究中,采用免疫组化方法分析59例OSCC原发肿瘤中PD-L1表达(肿瘤比例评分[TPS],联合阳性评分[CPS])和c-MET表达(h评分,基于百分比评分)。24例患者的原发肿瘤-淋巴结转移配对可作为配对空间异质性分析的基础。评估原发肿瘤和转移瘤之间的生物标志物一致性以及与临床病理参数的关联。结果:PD-L1和c-MET在原发肿瘤中频繁表达,但在匹配的淋巴结转移中表达水平明显降低。探索性分析显示,原发性肿瘤中PD-L1的高表达与淋巴结转移有关,而c-MET的表达与淋巴结状态无显著关联。PD-L1与c-MET表达无明显相关性。此外,原发肿瘤和淋巴结转移之间PD-L1 CPS状态的不一致导致了相当一部分匹配病例的不同生物标志物分类。在探索性分析中,生物标志物表达和原发性肿瘤-淋巴结不一致与复发没有显著相关性,尽管事件数量有限,无法得出明确的结论。结论:我们的研究结果表明,PD-L1和c-MET在OSCC中的表达具有明显的空间异质性,并揭示了原发肿瘤和淋巴结转移之间的特异性生物标志物表达模式。观察到的肿瘤腔室之间的不一致性值得在更大规模的前瞻性研究中进一步研究,以确定其在OSCC生物标志物评估中的生物学和潜在临床相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书